0000899243-23-018762.txt : 20230912 0000899243-23-018762.hdr.sgml : 20230912 20230912182024 ACCESSION NUMBER: 0000899243-23-018762 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230908 FILED AS OF DATE: 20230912 DATE AS OF CHANGE: 20230912 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Perkins Adelene Q CENTRAL INDEX KEY: 0001375124 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31141 FILM NUMBER: 231251219 MAIL ADDRESS: STREET 1: C/O INFINITY PHARMACEUTICALS, INC. STREET 2: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INFINITY PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001113148 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330655706 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1100 MASSACHUSETTS AVENUE STREET 2: FLOOR 4 CITY: CAMBRIDGE STATE: MA ZIP: 02138 BUSINESS PHONE: 6174531000 MAIL ADDRESS: STREET 1: 1100 MASSACHUSETTS AVENUE STREET 2: FLOOR 4 CITY: CAMBRIDGE STATE: MA ZIP: 02138 FORMER COMPANY: FORMER CONFORMED NAME: INFINITY PHARMACEUTICALS, INC./NEW/ DATE OF NAME CHANGE: 20060913 FORMER COMPANY: FORMER CONFORMED NAME: DISCOVERY PARTNERS INTERNATIONAL INC DATE OF NAME CHANGE: 20000428 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-09-08 0 0001113148 INFINITY PHARMACEUTICALS, INC. INFI 0001375124 Perkins Adelene Q C/O INFINITY PHARMACEUTICALS, INC. 1100 MASSACHUSETTS AVENUE, FLOOR 4 CAMBRIDGE MA 02138 1 0 0 0 1 Common Stock 2023-09-09 4 M 0 768133 A 1585487 D Common Stock 2023-09-12 4 S 0 410196 0.07 D 1175291 D Common Stock 16446.7945 I 401(K) Restricted Stock Unit 2023-09-09 4 M 0 768133 0.00 D Common Stock 768133 0 D Restricted stock units ("RSUs") convert into Common Stock of the issuer on a one-for-one basis. This transaction represents the settlement of RSUs in shares of Common Stock on their vesting date. Pursuant to a binding contract entered into between the issuer and the reporting person on August 15, 2022, this represents the shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the RSUs listed in Table II. Such binding contract is intended to be consistent with the affirmative action defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. This sale does not represent a discretionary trade by the reporting person. On August 11, 2022, the reporting person was granted RSUs, of which all 768,133 vested as of September 9, 2023. /s/ Adelene Q. Perkins 2023-09-12